What is Elekta?
Headquartered in Stockholm, Sweden, Elekta specializes in the development and manufacturing of advanced medical technologies designed for the treatment of cancer and complex brain disorders. The company's comprehensive portfolio includes state-of-the-art linear accelerators, the renowned Gamma Knife radiosurgery systems, and sophisticated brachytherapy solutions. By integrating oncology information systems with precision treatment planning software, Elekta provides clinical management tools that are essential for modern radiotherapy workflows. Its market position is defined by a commitment to clinical excellence and technological innovation, serving healthcare providers worldwide with equipment that enhances patient outcomes through high-precision intervention.
How much funding has Elekta raised?
Elekta has raised a total of $200M across 1 funding round:
Debt
$200M
Debt (2011): $200M, investors not publicly disclosed
Key Investors in Elekta
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Elekta?
With this major strategic investment, Elekta is positioned to accelerate its research and development pipeline, focusing on the next generation of oncology software and hardware integration. The company is likely to prioritize the expansion of its digital health ecosystem, leveraging data-driven insights to improve treatment efficacy. As the global demand for non-invasive cancer therapies continues to rise, Elekta's strategic roadmap will likely emphasize global market penetration and the refinement of its clinical management platforms. This capital deployment serves as a catalyst for maintaining its competitive edge in the high-stakes medical device industry, ensuring that its technological infrastructure remains at the forefront of clinical oncology standards.
See full Elekta company page
